인간 간 모델 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 용도별, 최종 용도별, 지역별, 부문별 예측(2025-2030년)

Human Liver Model Market Size, Share & Trends Analysis Report By Product (2D Models, 3D Models), By Application (ADME Studies, Toxicology Testing), By End Use, By Region, And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,609,000

Unprintable PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,950 ￦ 10,055,000

Printable PDF (5-User License)

PDF 보고서를 동일 기업의 5명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,950 ￦ 12,949,000

Printable PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

인간 간 모델 시장 규모와 동향 :

세계의 인간 간 모델 시장 규모는 2024년에 13억 4,000만 달러로, 2025-2030년 연평균 14.04% 성장할 것으로 예상됩니다.

간질환 유병률 증가, 장기 프린팅 기술의 발전, 간암 치료제에 대한 수요 증가 등이 이 산업의 성장 동력이 되고 있습니다.

보건 자원 및 서비스 기관에 따르면 2023년 미국에서는 10만6800명이 장기 이식을 기다리고 있습니다. 의료 상황은 진화하고 있으며, 3D 프린팅 기술의 발전은 장기 부족을 해결하고 전 세계에서 환자 치료를 개선함으로써 의료를 변화시키려고 노력하고 있습니다.

간 질환의 유병률은 전 세계에서 증가 추세에 있으며, 인간 간 모델과 같은 고급 연구 툴에 대한 수요가 증가하고 있습니다. 비알코올성 지방간질환(NAFLD), 알코올성 간질환, 바이러스성 간염, 간암과 같은 만성 간질환은 건강에 해로운 식습관, 좌식 생활습관, 알코올 섭취, 바이러스 감염 등의 요인으로 인해 점점 더 흔해지고 있습니다. 예를 들어 NAFLD는 유럽과 미국에서 가장 흔한 만성 간질환으로 전 세계 인구의 약 25%가 앓고 있습니다. 이러한 간 질환의 유병률이 크게 증가함에 따라 연구 및 의약품 개발을 지원하기 위해 보다 정확하고 효율적인 인간 간 모델에 대한 긴급한 요구가 증가하고 있습니다.

장기 3D 프린팅 기술은 특히 인간 간 모델 개발에서 최근 괄목할 만한 발전을 이루었습니다. 이러한 발전은 연구 목적에 따라 보다 정확하고 개별화된 모델을 제공함으로써 재생의료와 약물 테스트에 혁명을 일으키고 있습니다. 예를 들어 2023년 2월 캘리포니아대학교 샌디에이고 캠퍼스 연구진은 높은 세포 밀도, 생존율, 정확한 조형 해상도로 3D 프린팅 조직 바이오프린팅의 과제를 해결하는 데 큰 진전을 이루었습니다.

목차

제1장 분석 방법·범위

제2장 개요

제3장 인간 간 모델 시장 : 변동 요인·경향·범위

• 시장 연관 전망
  • 모시장 전망
  • 관련/부수 시장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 인간 간 모델 시장 : 분석 툴
  • 업계 분석 : Porter의 산업 분석
  • PESTEL 분석
  • COVID-19의 영향 분석

제4장 인간 간 모델 시장 : 제품별 추정·동향 분석

• 제품별 대시보드
• 인간 간 모델 시장 : 제품별 변동 분석
• 인간 간 모델 시장 : 시장 규모 예측과 동향 분석, 제품별(2018-2030년)
• 2D 모델
  • 세포주
  • 일차 세포
• 3D 모델
  • Liver on Chip
  • 오가노이드
  • 스페로이드
  • 기타

제5장 인간 간 모델 시장 : 용도별 추정·동향 분석

• 용도별 대시보드
• 인간 간 모델 시장 : 용도별 변동 분석
• 인간 간 모델 시장 : 시장 규모 예측과 동향 분석, 용도별(2018-2030년)
• ADME 연구
• 독성 시험
• 질환 모델화
• 기타

제6장 인간 간 모델 시장 : 최종 용도별 추정·동향 분석

• 최종 용도별 대시보드
• 인간 간 모델 시장 : 최종 용도별 변동 분석
• 인간 간 모델 시장 : 시장 규모 예측과 동향 분석, 최종 용도별(2018-2030년)
• 학술연구기관
• 제약·바이오 제품 기업
• CRO

제7장 인간 간 모델 시장 : 지역별 추정·동향 분석

• 인간 간 모델 시장 : 지역별 추정·동향 분석, 제품별, 용도별, 최종 용도별
• 시장 대시보드 : 지역별
• 시장 점유율 : 지역별(2024년·2030년)
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 덴마크
  • 스웨덴
  • 노르웨이
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 태국
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트
  • 쿠웨이트

제8장 경쟁 구도

• 기업/경쟁의 분류
• 전략 지도제작
• 기업 시장 현황 분석(2024년)
• 기업 개요
  • ATCC
  • Merck KGaA
  • AcceGen
  • ZenBio, Inc.
  • Organovo Holdings Inc.
  • BioIVT
  • InSphero
  • Emulate, Inc.
  • Mimetas
  • CN Bio Innovations Ltd

KSA

영문 목차

영문목차

Human Liver Model Market Size & Trends:

The global human liver model market size was valued at USD 1.34 billion in 2024 and is projected to grow at a CAGR of 14.04% from 2025 to 2030. The industry is driven by the increasing prevalence of liver diseases, advancements in organ printing technologies, and increased demand for therapeutic drugs for liver cancer, which is expected to propel its growth.

According to the Health Resources & Services Administration, in 2023, in the U.S., 106,800 individuals are waiting for organ transplants. The healthcare landscape is evolving, and advancements in 3D printing technology are set to transform healthcare by addressing organ shortages and improving patient care globally.

The prevalence of liver diseases is on the rise globally, leading to a growing demand for advanced research tools, including human liver models. Chronic liver conditions such as non-alcoholic fatty liver disease (NAFLD), alcoholic liver disease, viral hepatitis, and liver cancer are becoming increasingly common due to factors such as unhealthy diets, sedentary lifestyles, alcohol consumption, and viral infections. For instance, NAFLD emerged as the most prevalent chronic liver disorder in Western countries, affecting approximately 25% of the global population. This significant rise in the prevalence of liver diseases has driven the urgent need for more accurate and efficient human liver models to support research and drug development efforts.

Organ 3D printing technologies have advanced significantly recently, particularly in developing human liver models. These advancements have revolutionized regenerative medicine and drug testing by providing more accurate and personalized models for research purposes. For instance, in February 2023, researchers at the University of California San Diego made significant progress in addressing challenging issues in bio-printing 3D-engineered tissues, achieving high cell density, viability, and precise fabrication resolution.

Global Human Liver Model Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global human liver model market report on the basis of product, application, end-use, and region.

• Product Outlook (Revenue, USD Million, 2018 - 2030)
• 2D Models
  • Cell lines
  • Primary Cells
• 3D Models
  • Liver on Chip
  • Organoids
  • Spheroids
  • Others
• Application Outlook (Revenue, USD Million, 2018 - 2030)
• ADME Studies
• Toxicology Testing
• Disease Modelling
• Others
• End Use Outlook (Revenue, USD Million, 2018 - 2030)
• Academic & Research Institutes
• Pharmaceutical & Biotechnology Companies
• Contract Research Organizations
• Regional Outlook (Revenue, USD Million, 2018 - 2030)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Application
  • 1.2.3. End-use
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Human Liver Model Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook.
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Increasing prevalence of liver diseases
    • 3.2.1.2. Advancements in organ printing technologies
    • 3.2.1.3. Increased demand for therapeutic drugs for liver cancer
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High costs and complexity associated with maintaining human liver models
• 3.3. Human Liver Model Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTEL Analysis
  • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Human Liver Model Market: Product Estimates & Trend Analysis

• 4.1. Product Segment Dashboard
• 4.2. Global Human Liver Model Market Product Movement Analysis, 2024 & 2030 (USD Million)
• 4.3. Global Human Liver Model Market Size and Trend Analysis, by Product, 2018 to 2030 (USD Million)
• 4.4. 2D Models
  • 4.4.1. 2D models market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.2. Cell Lines
    • 4.4.2.1. Cell Lines market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.3. Primary Cells
    • 4.4.3.1. Primary Cells market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. 3D Models
  • 4.5.1. 3D models market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5.2. Liver on Chip
    • 4.5.2.1. Liver on Chip market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5.3. Organoids
    • 4.5.3.1. Organoids market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5.4. Spheroids
    • 4.5.4.1. Spheroids market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5.5. Others
    • 4.5.5.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Human Liver Model Market: Application Estimates & Trend Analysis

• 5.1. Application Segment Dashboard
• 5.2. Global Human Liver Model Market Application Movement Analysis, 2024 & 2030 (USD Million)
• 5.3. Global Human Liver Model Market Size and Trend Analysis, by Application, 2018 to 2030 (USD Million)
• 5.4. ADME Studies
  • 5.4.1. ADME Studies market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Toxicology Testing
  • 5.5.1. Toxicology Testing market estimates and forecasts 2018 to 2030 (USD Million)
• 5.6. Disease Modelling
  • 5.6.1. Disease Modelling market estimates and forecasts 2018 to 2030 (USD Million)
• 5.7. Others
  • 5.7.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Human Liver Model Market: End-use Estimates & Trend Analysis

• 6.1. End-use Segment Dashboard
• 6.2. Global Human Liver Model Market End-use Movement Analysis, 2024 & 2030 (USD Million)
• 6.3. Global Human Liver Model Market Size and Trend Analysis, by End-use, 2018 to 2030 (USD Million)
• 6.4. Academic & Research Institutes
  • 6.4.1. Academic & Research Institutes market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Pharmaceutical & Bioproduct Companies
  • 6.5.1. Pharmaceutical & Bioproduct Companies market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Contract Research Organizations
  • 6.6.1. Contract Research Organizations market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Human Liver Model Market: Regional Estimates & Trend Analysis

• 7.1. Human Liver Model Market: Regional Estimates & Trend Analysis by Product, Application, and End-use
• 7.2. Regional Market Dashboard
• 7.3. Regional Market Share Analysis, 2024 & 2030
• 7.4. North America
  • 7.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.2. U.S.
    • 7.4.2.1. Key country dynamics
    • 7.4.2.2. Competitive scenario
    • 7.4.2.3. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.3. Canada
    • 7.4.3.1. Key country dynamics
    • 7.4.3.2. Competitive scenario
    • 7.4.3.3. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.4. Mexico
    • 7.4.4.1. Key country dynamics
    • 7.4.4.2. Competitive scenario
    • 7.4.4.3. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 7.5. Europe
  • 7.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.2. UK
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Competitive scenario
    • 7.5.2.3. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.3. Germany
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Competitive scenario
    • 7.5.3.3. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.4. France
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Competitive scenario
    • 7.5.4.3. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.5. Italy
    • 7.5.5.1. Key country dynamics
    • 7.5.5.2. Competitive scenario
    • 7.5.5.3. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.6. Spain
    • 7.5.6.1. Key country dynamics
    • 7.5.6.2. Competitive scenario
    • 7.5.6.3. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.7. Denmark
    • 7.5.7.1. Key country dynamics
    • 7.5.7.2. Competitive scenario
    • 7.5.7.3. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.8. Sweden
    • 7.5.8.1. Key country dynamics
    • 7.5.8.2. Competitive scenario
    • 7.5.8.3. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.9. Norway
    • 7.5.9.1. Key country dynamics
    • 7.5.9.2. Competitive scenario
    • 7.5.9.3. Norway market estimates and forecasts 2018 to 2030 (USD Million)
• 7.6. Asia Pacific
  • 7.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.2. Japan
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Competitive scenario
    • 7.6.2.3. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.3. China
    • 7.6.3.1. Key country dynamics
    • 7.6.3.2. Competitive scenario
    • 7.6.3.3. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.4. India
    • 7.6.4.1. Key country dynamics
    • 7.6.4.2. Competitive scenario
    • 7.6.4.3. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.5. Australia
    • 7.6.5.1. Key country dynamics
    • 7.6.5.2. Competitive scenario
    • 7.6.5.3. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.6. South Korea
    • 7.6.6.1. Key country dynamics
    • 7.6.6.2. Competitive scenario
    • 7.6.6.3. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.7. Thailand
    • 7.6.7.1. Key country dynamics
    • 7.6.7.2. Competitive scenario
    • 7.6.7.3. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 7.7. Latin America
  • 7.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.2. Brazil
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Competitive scenario
    • 7.7.2.3. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.3. Argentina
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Competitive scenario
    • 7.7.3.3. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 7.8. MEA
  • 7.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8.2. South Africa
    • 7.8.2.1. Key country dynamics
    • 7.8.2.2. Competitive scenario
    • 7.8.2.3. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8.3. Saudi Arabia
    • 7.8.3.1. Key country dynamics
    • 7.8.3.2. Competitive scenario
    • 7.8.3.3. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8.4. UAE
    • 7.8.4.1. Key country dynamics
    • 7.8.4.2. Competitive scenario
    • 7.8.4.3. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8.5. Kuwait
    • 7.8.5.1. Key country dynamics
    • 7.8.5.2. Competitive scenario
    • 7.8.5.3. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Company/Competition Categorization
• 8.2. Strategy Mapping
• 8.3. Company Market Position Analysis, 2024
• 8.4. Company Profiles
  • 8.4.1. ATCC
    • 8.4.1.1. Company overview
    • 8.4.1.2. Financial performance
    • 8.4.1.3. Product benchmarking
    • 8.4.1.4. Strategic initiatives
  • 8.4.2. Merck KGaA
    • 8.4.2.1. Company overview
    • 8.4.2.2. Financial performance
    • 8.4.2.3. Product benchmarking
    • 8.4.2.4. Strategic initiatives
  • 8.4.3. AcceGen
    • 8.4.3.1. Company overview
    • 8.4.3.2. Financial performance
    • 8.4.3.3. Product benchmarking
    • 8.4.3.4. Strategic initiatives
  • 8.4.4. ZenBio, Inc.
    • 8.4.4.1. Company overview
    • 8.4.4.2. Financial performance
    • 8.4.4.3. Product benchmarking
    • 8.4.4.4. Strategic initiatives
  • 8.4.5. Organovo Holdings Inc.
    • 8.4.5.1. Company overview
    • 8.4.5.2. Financial performance
    • 8.4.5.3. Product benchmarking
    • 8.4.5.4. Strategic initiatives
  • 8.4.6. BioIVT
    • 8.4.6.1. Company overview
    • 8.4.6.2. Financial performance
    • 8.4.6.3. Product benchmarking
    • 8.4.6.4. Strategic initiatives
  • 8.4.7. InSphero
    • 8.4.7.1. Company overview
    • 8.4.7.2. Financial performance
    • 8.4.7.3. Product benchmarking
    • 8.4.7.4. Strategic initiatives
  • 8.4.8. Emulate, Inc.
    • 8.4.8.1. Company overview
    • 8.4.8.2. Financial performance
    • 8.4.8.3. Product benchmarking
    • 8.4.8.4. Strategic initiatives
  • 8.4.9. Mimetas
    • 8.4.9.1. Company overview
    • 8.4.9.2. Financial performance
    • 8.4.9.3. Product benchmarking
    • 8.4.9.4. Strategic initiatives
  • 8.4.10. CN Bio Innovations Ltd
    • 8.4.10.1. Company overview
    • 8.4.10.2. Financial performance
    • 8.4.10.3. Product benchmarking
    • 8.4.10.4. Strategic initiatives

관련자료